|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pérez-Tomás R: Multidrug resistance:
retrospect and prospects in anti-cancer drug treatment. Curr Med
Chem. 13:1859–1876. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
O’Connor R: A review of mechanisms of
circumvention and modulation of chemotherapeutic drug resistance.
Curr Cancer Drug Targets. 9:273–280. 2009. View Article : Google Scholar
|
|
5
|
Gerke V, Creutz CE and Moss SE: Annexins:
linking Ca2+ signalling to membrane dynamics. Nat Rev
Mol Cell Biol. 6:449–461. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang X, Liu S, Guo C, Zong J and Sun MZ:
The association of Annexin A2 and cancers. Clin Transl Oncol.
14:634–640. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bharadwaj A, Bydoun M, Holloway R and
Waisman D: Annexin A2 heterotetramer: structure and function. Int J
Mol Sci. 14:6259–6305. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu B, Zhang F, Yu M, et al: Up-regulation
of Anxa2 gene promotes proliferation and invasion of breast cancer
MCF-7 cells. Cell Prolif. 45:189–198. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ohno Y, Izumi M, Kawamura T, Nishimura T,
Mukai K and Tachibana M: Annexin II represents metastatic potential
in clear-cell renal cell carcinoma. Br J Cancer. 101:287–294. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Emoto K, Sawada H, Yamada Y, et al:
Annexin II overexpression is correlated with poor prognosis in
human gastric carcinoma. Anticancer Res. 21:1339–1345.
2001.PubMed/NCBI
|
|
11
|
Gao H, Yu B, Yan Y, et al: Correlation of
expression levels of ANXA2, PGAM1, and CALR with glioma grade and
prognosis. J Neurosurg. 118:846–853. 2013. View Article : Google Scholar
|
|
12
|
Bao H, Jiang M, Zhu M, Sheng F, Ruan J and
Ruan C: Overexpression of Annexin II affects the proliferation,
apoptosis, invasion and production of proangiogenic factors in
multiple myeloma. Int J Hematol. 90:177–185. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gillette JM, Chan DC and Nielsen-Preiss
SM: Annexin 2 expression is reduced in human osteosarcoma
metastases. J Cell Biochem. 92:820–832. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pena-Alonso E, Rodrigo JP, Parra IC, et
al: Annexin A2 localizes to the basal epithelial layer and is
down-regulated in dysplasia and head and neck squamous cell
carcinoma. Cancer Lett. 263:89–98. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Longerich T, Haller MT, Mogler C, et al:
Annexin A2 as a differential diagnostic marker of hepatocellular
tumors. Pathol Res Pract. 207:8–14. 2011. View Article : Google Scholar
|
|
16
|
Mohammad HS, Kurokohchi K, Yoneyama H, et
al: Annexin A2 expression and phosphorylation are up-regulated in
hepatocellular carcinoma. Int J Oncol. 33:1157–1163.
2008.PubMed/NCBI
|
|
17
|
Zhang HJ, Yao DF, Yao M, et al: Expression
characteristics and diagnostic value of annexin A2 in
hepatocellular carcinoma. World J Gastroenterol. 18:5897–5904.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang W, Zhao P, Xu XL, et al: Annexin A2
promotes the migration and invasion of human hepatocellular
carcinoma cells in vitro by regulating the shedding of
CD147-harboring microvesicles from tumor cells. PLoS One.
8:e672682013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ye X, Guo Y, Zhang Q, et al: βKlotho
suppresses tumor growth in hepatocellular carcinoma by regulating
Akt/GSK-3β/cyclin D1 signaling pathway. PLoS One. 8:e556152013.
View Article : Google Scholar
|
|
20
|
Tomimaru Y, Eguchi H, Nagano H, et al:
MicroRNA-21 induces resistance to the anti-tumour effect of
interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J
Cancer. 103:1617–1626. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kanda T, Yokosuka O, Imazeki F, Arai M and
Saisho H: Enhanced sensitivity of human hepatoma cells to
5-fluorouracil by small interfering RNA targeting Bcl-2. DNA Cell
Biol. 24:805–809. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wong CM, Fan ST and Ng IO: beta-Catenin
mutation and overexpression in hepatocellular carcinoma:
clinicopathologic and prognostic significance. Cancer. 92:136–145.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nhieu JT, Renard CA, Wei Y, Cherqui D,
Zafrani ES and Buendia MA: Nuclear accumulation of mutated
beta-catenin in hepatocellular carcinoma is associated with
increased cell proliferation. Am J Pathol. 155:703–710. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Herencia C, Martinez-Moreno JM, Herrera C,
et al: Nuclear translocation of β-catenin during mesenchymal stem
cells differentiation into hepatocytes is associated with a tumoral
phenotype. PLoS One. 7:e346562012. View Article : Google Scholar
|
|
25
|
Llovet JM and Bruix J: Molecular targeted
therapies in hepatocellular carcinoma. Hepatology. 48:1312–1327.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang YJ, Jiang W, Chen CJ, et al:
Amplification and overexpression of cyclin D1 in human
hepatocellular carcinoma. Biochem Biophys Res Commun.
196:1010–1016. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zeng G, Apte U, Cieply B, Singh S and
Monga SP: siRNA-mediated beta-catenin knockdown in human hepatoma
cells results in decreased growth and survival. Neoplasia.
9:951–959. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Waly Raphael S, Yangde Z and Yuxiang C:
Hepatocellular carcinoma: focus on different aspects of management.
ISRN Oncol. 2012:4216732012.PubMed/NCBI
|
|
29
|
Tong SW, Yang YX, Hu HD, et al: Proteomic
investigation of 5-fluorouracil resistance in a human
hepatocellular carcinoma cell line. J Cell Biochem. 113:1671–1680.
2012.
|
|
30
|
Noda T, Nagano H, Takemasa I, et al:
Activation of Wnt/beta-catenin signalling pathway induces
chemoresistance to interferon-alpha/5-fluorouracil combination
therapy for hepatocellular carcinoma. Br J Cancer. 100:1647–1658.
2009. View Article : Google Scholar : PubMed/NCBI
|
